• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boehringer Ingelheim forms partnerships

Boehringer Ingelheim forms partnerships

March 16, 2011
CenterWatch Staff

Boehringer Ingelheim has entered into an antibody deal with fellow German firm MorphoSys and signed a diabetes technology pact with Depomed, according to Pharma Times.

The MorphoSys agreement covers the process development and manufacturing of additional clinical material for MOR208, a monoclonal anti-CD19 antibody for the treatment of chronic lymphocytic leukaemia and potentially other B-cell malignancies. It is currently being evaluated in a phase I trial in the U.S. by MorphoSys's partner Xencor.

Simon Sturge, head of the biopharmaceuticals division at Boehringer, said the combination of MorphoSys' track record in the discovery and clinical side of antibody-based therapeutics "and our proven competence in technical development and manufacturing will be an optimal fit."

Boehringer has obtained worldwide rights to Depomed's Acuform gastric retentive drug delivery technology to develop certain fixed-dose combination products which include extended-release metformin and Boehringer compounds for type II diabetes.

Boehringer is paying a $12.5 million license fee, $10 million upfront and an additional $2.5 million payable upon delivery of experimental batches of prototype formulations. Depomed is also eligible to receive additional milestone payments and royalties.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing